Stockscreener 앱 받기
1.00
5.66%
-0.06
시간 외 거래:
1.10
0.10
+10.00%
전일 마감가:
$1.06
열려 있는:
$1.02
하루 거래량:
1.10M
Relative Volume:
0.89
시가총액:
$71.13M
수익:
-
순이익/손실:
$-192.96M
주가수익비율:
-0.303
EPS:
-3.3
순현금흐름:
$-167.04M
1주 성능:
-18.70%
1개월 성능:
-30.56%
6개월 성능:
-51.46%
1년 성능:
-80.69%
1일 변동 폭
$0.99
$1.06
1주일 범위
$0.99
$1.235
52주 변동 폭
$0.99
$5.66
Ventyx Biosciences Inc Stock (VTYX) Company Profile
명칭
Ventyx Biosciences Inc
전화
(858) 945-2393
주소
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
VTYX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
1.00 | 71.13M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-03-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-11-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Wells Fargo | Overweight |
| 2022-12-19 | 개시 | Goldman | Buy |
| 2022-11-17 | 개시 | Morgan Stanley | Overweight |
| 2022-09-07 | 개시 | Stifel | Buy |
| 2022-09-01 | 개시 | H.C. Wainwright | Buy |
| 2022-05-09 | 개시 | Credit Suisse | Outperform |
| 2022-03-31 | 개시 | Canaccord Genuity | Buy |
| 2022-02-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-15 | 개시 | Jefferies | Buy |
| 2021-11-15 | 개시 | Piper Sandler | Overweight |
모두보기
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
Ventyx Biosciences chief scientific officer John Nuss sells $2,019 in shares - Investing.com India
VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Stock Traders Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Ventyx boosts advisory board with top scientists By Investing.com - Investing.com South Africa
Ventyx boosts advisory board with top scientists - Investing.com
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts - GlobeNewswire
Insiders' US$1.26m Investments In Red Following Ventyx Biosciences' US$11m Dip In Market Value - simplywall.st
Ventyx Biosciences stock hits 52-week low at $1.21 amid market challenges - Investing.com
Ventyx Biosciences stock hits 52-week low at $1.28 amid market challenges - Investing.com Australia
Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges - MSN
Ventyx Biosciences stock hits 52-week low at $1.37 amid market challenges - Investing.com Australia
Rhumbline Advisers Acquires 40,813 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights – VTYX - ACCESS Newswire
Ventyx Biosciences Reports 2024 Financial Results and Progress - TipRanks
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges - Investing.com India
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges By Investing.com - Investing.com South Africa
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVTYX - ACCESS Newswire
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm - ACCESS Newswire
Ventyx Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences reports Q4 EPS (41c), consensus (55c) - TipRanks
VTYXVentyx Biosciences, Inc. Latest Stock News & Market Updates - Stock Titan
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ventyx Biosciences Reports Fourth Quarter and Full Year - GlobeNewswire
Can Ventyx's $252.9M Cash Cushion and 3 Upcoming Trial Readouts Excite Biotech Investors? - StockTitan
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress - Yahoo Finance
Ventyx Biosciences stock hits 52-week low at $1.57 By Investing.com - Investing.com Australia
Ventyx Biosciences stock hits 52-week low at $1.57 - Investing.com India
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Ventyx Biosciences (VTYX) to Release Earnings on Tuesday - Defense World
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Ventyx Biosciences Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences Announces Presentation of Data from the - GlobeNewswire
Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease - TipRanks
Ventyx reports mixed results in Crohn's disease trial By Investing.com - Investing.com Australia
Ventyx reports mixed results in Crohn's disease trial - Investing.com India
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 - The Bakersfield Californian
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025 - Yahoo Finance
SG Americas Securities LLC Cuts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
RSLS stock touches 52-week low at $2.57 amid market challenges - MSN
Ventyx Biosciences Inc (VTYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):